Study to Prevent Pre-eclampsia with Low Dose Acetylsalicylic Acid in Pregnant Women After Frozen Embryo Transfer

What this Trial Is About

This research aims to evaluate the effect of low dose acetylsalicylic acid as a preventive treatment for pre-eclampsia in pregnant women who have undergone frozen embryo transfer. The study is a prospective, multicenter, interventional, randomized controlled trial designed to compare the incidence of pre-eclampsia between women treated with acetylsalicylic acid and those who are not. It includes women with natural, modified natural, or hormone replacement treatment HRT cycles who have a confirmed pregnancy at week 6 of amenorrhea. Participants will be randomly assigned to one of two groups a treatment group receiving 160 mg of acetylsalicylic acid daily from embryo transfer until 36 weeks of amenorrhea, and a control group receiving no treatment. The study will monitor women in both groups with visits twice a month, including regular prenatal visits and phone calls. The trial will run up to delivery, with a maximum participant duration of 12 months, and overall study duration up to 4 years. During the study, participants will attend regular prenatal visits and receive phone follow-ups twice monthly. Researchers will monitor the occurrence of pre-eclampsia and miscarriage rates across different cycle types natural, modified natural, and HRT. The primary outcome is the number of women developing pre-eclampsia in treated versus untreated groups. Safety and treatment adherence will be assessed throughout, and participants will be followed until delivery.

Treatment Preventive for Pre-eclampsia by Acetylsalicylic Acid in Women Who Underwent Frozen Embryo Transfer